Quick Answer
Viridian Therapeutics, Inc.DE reported Long-Term Debt of $20.58 million for fiscal year 2024.
Viridian Therapeutics, Inc.DE Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2024 | $20.58M | +1.9% |
| 2023 | $20.20M | +335.0% |
| 2022 | $4.64M | — |
| 2021 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.89M | +1.8% | +69.1% |
| June 30, 2025 | $12.35M | -29.4% | -40.3% |
| March 31, 2025 | $20.68M | +1.8% | +0.5% |
| December 31, 2024 | $20.58M | +1.9% | +0.3% |
| September 30, 2024 | $20.52M | +2.6% | +17.4% |
| June 30, 2024 | $17.49M | +271.4% | -14.0% |
| March 31, 2024 | $20.33M | +334.6% | +0.6% |
| December 31, 2023 | $20.20M | +335.0% | +1.0% |
- Viridian Therapeutics, Inc.DE showed an increase of +1.9% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from Viridian Therapeutics, Inc.DE’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 3, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: